Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab
出版年份 2019 全文链接
标题
Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab
作者
关键词
<em class="EmphasisTypeItalic ">HER2</em> amplification, Circulating DNA, Metastatic colorectal cancer, Cetuximab resistance, Dynamic monitor
出版物
Clinical & Translational Oncology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-10-01
DOI
10.1007/s12094-019-02215-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
- (2019) Funda Meric-Bernstam et al. LANCET ONCOLOGY
- Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
- (2018) S Siena et al. ANNALS OF ONCOLOGY
- Advantage of Next-Generation Sequencing in Dynamic Monitoring of Circulating Tumor DNA over Droplet Digital PCR in Cetuximab Treated Colorectal Cancer Patients
- (2018) Hangyu Zhang et al. Translational Oncology
- Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer
- (2017) Alan P. Venook et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers
- (2017) Mohamed E. Salem et al. Oncotarget
- Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
- (2016) Filippo Pietrantonio et al. CLINICAL CANCER RESEARCH
- HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials
- (2016) Susan D Richman et al. JOURNAL OF PATHOLOGY
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis
- (2016) Soo Kyung Nam et al. PLoS One
- A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies
- (2015) John F. Deeken et al. CANCER
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
- (2015) Emanuele Valtorta et al. MODERN PATHOLOGY
- Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
- (2014) E. Missiaglia et al. ANNALS OF ONCOLOGY
- HER2/neu testing in primary colorectal carcinoma
- (2014) B Ingold Heppner et al. BRITISH JOURNAL OF CANCER
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
- (2012) Sandra Misale et al. NATURE
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
- (2012) Luis A. Diaz Jr et al. NATURE
- Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
- (2012) Clara Montagut et al. NATURE MEDICINE
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- (2011) K. Yonesaka et al. Science Translational Medicine
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started